LIVE NCPD WEBINAR: September 2, 2021, 5:00 PM – 6:00 PM Eastern Time

Fall Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Prostate Cancer

Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, September 2, 2021 from 5:00 PM – 6:00 PM Eastern Time

Mary-Ellen Taplin, MD
Professor of Medicine
Harvard School of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts
Kathy D Burns, RN, MSN, AGACNP-BC, OCN
GU Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Topics to Be Discussed

  • Overview of the incidence and prognosis of prostate cancer; patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care (eg, Gleason score, PSA, PSA doubling time)
  • Defining nonmetastatic (M0) castration-resistant prostate cancer (CRPC) in clinical practice; efficacy of next-generation antiandrogen agents (apalutamide, darolutamide and enzalutamide), practical integration into the management of M0 disease and the spectrum and frequency of toxicities, including CNS-related adverse events (eg, fatigue, seizure, falls)
  • Clinical, biologic and practical factors (eg, age, duration of therapy, extent and sites of metastases) guiding the choice between secondary hormonal therapy and chemotherapy for metastatic hormone-sensitive prostate cancer; effectiveness and tolerability of antiandrogen agents (eg, enzalutamide or apalutamide) or chemotherapy (eg, docetaxel) in combination with androgen deprivation therapy (ADT) compared to ADT alone
  • Clinical and biologic factors affecting the selection and sequencing of secondary hormonal therapy, chemotherapy and other therapeutic modalities (eg, cabazitaxel, radium-223) for patients with metastatic CRPC
  • Rationale and clinical strategy for molecular testing for deleterious germline or somatic HRR (homologous recombination repair) gene mutations in patients with metastatic CRPC; mechanism of action, effectiveness and side effects of PARP inhibitors (ie, olaparib and rucaparib) and practical incorporation into therapy

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Apply existing and emerging research data in the therapeutic and supportive care of patients with early and advanced prostate cancer.
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Counsel patients with hormone-sensitive metastatic prostate cancer regarding the use of cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
  • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic CRPC.
  • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or other DNA damage repair pathway abnormalities, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
  • Educate patients about the side effects associated with approved therapies commonly used for advanced prostate cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Recall available data and the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Taplin has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms BurnsAdvisory Committee: EMD Serono Inc, Pfizer Inc; Speakers Bureau: Astellas, Aveo Pharmaceuticals, Exelixis Inc, Myovant Sciences, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.